HIGHBuilt-inProduct / Revenue mix
100%
ICLs
“10-K Item 1: 'Sales of ICLs accounted for approximately 100% of our total sales in fiscal 2025'”
STAA · Concentration risk · 10-K extracted
STAAR Surgical (STAA) concentration risks
Updated
The most significant concentration STAAR Surgical discloses is ICLs at 100%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: STAAR Surgical’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 4 disclosed concentrations
HIGH3
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inGeographic
91%
outside the United States
“10-K Item 1A: 'Activities outside the U.S. accounted for approximately 91% of our total sales during 2025.'”
HIGHOutside partySupplier
single-sourced raw materials
“10-K Item 1: 'Some of our raw materials are single-sourced due to regulatory constraints, cost effectiveness, availability, quality, and vendor reliability issues.'”
MEDIUMOutside partyCustomer
32%
China distributors
“10-K Item 1: 'Two customers, our China distributors who sell into China and Hong Kong, accounted for approximately 32% of our consolidated net sales during fiscal 2025.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06STAAR Surgical's concentration profile is about as structural as it gets: sales of its implantable collamer lenses (ICLs) accounted for approximately 100% of total sales in fiscal 2025, and activities outside the United States made up about 91% of total sales during 2025. These are not idiosyncratic counterparty risks but defining characteristics of the business itself — a single-product, internationally-driven model where the company's fortunes rise and fall with global ICL demand and non-U.S. market dynamics rather than with any one customer. Within that international base, China distributors stand out as a specific dependency: two customers, the company's China distributors selling into China and Hong Kong, accounted for approximately 32% of consolidated net sales in fiscal 2025 — a disclosed mid-range share concentrated in just two counterparties. Layered on top is a supply-side exposure: some raw materials are single-sourced due to regulatory, cost, availability, quality, and vendor-reliability constraints, an idiosyncratic risk where a shock at one supplier could compress margins or constrain production. Netting these together, STAAR's structural product and geographic concentration sets the overall risk backdrop, while the China distributor relationships and single-sourced materials are the more idiosyncratic lines that could move results if disrupted.
For the engine’s reasoning on STAA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| STAA● | STAAR Surgical Company | 3 | 1 | 0 | 4 |
| ANGO | AngioDynamics, Inc. | 2 | 1 | 0 | 3 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVR | Anteris Technologies Global Cor | 1 | 0 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.